Evidence map›Paper›PMID 32665955›Full record

ArticleOpen forum infectious diseases2020

Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer.

Michael J Boeckh, Ann M Arvin, Kathleen M Mullane, Luis H Camacho, Drew J Winston, Vicki A Morrison, Kimberly Hurtado, Jessie Durrand Hall, Lei Pang, Shu-Chih Su and 4 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01229267 phase3completednot on this map

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2010 to 2015Enrolled1,257ConditionsHerpes ZosterArmsV212, Matching placebo
NCT01254630 phase3completednot on this map

A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2011 to 2017Enrolled5,305ConditionsHerpes ZosterArmsV212, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Vaccines for preventing infections in adults with solid tumours.The Cochrane database of systematic reviews · 2025
    Pooled it
  4. Trial
  5. Review
  6. Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Michael J BoeckhVaccine and Infectious Disease & Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Ann M ArvinMicrobiology & Immunology Departments, Stanford University School of Medicine, Stanford, California, USA.
Kathleen M MullaneDepartment of Medicine, University of Chicago, Chicago, Illinois, USA.
Luis H CamachoMedical Oncology, Oncology Consultants, Houston, Texas, USA.
Drew J WinstonDepartment of Medicine, University of California Los Angeles Medical Center, Los Angeles, California, USA.
Vicki A MorrisonHematology Oncology Division, Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, USA.
Kimberly HurtadoMerck & Co., Inc., Kenilworth, New Jersey, USA.
Jessie Durrand HallMerck & Co., Inc., Kenilworth, New Jersey, USA.
Lei PangMerck & Co., Inc., Kenilworth, New Jersey, USA.
Shu-Chih SuMerck & Co., Inc., Kenilworth, New Jersey, USA.
Susan S KaplanMerck & Co., Inc., Kenilworth, New Jersey, USA.
Paula W AnnunziatoMerck & Co., Inc., Kenilworth, New Jersey, USA.
Zoran PopmihajlovMerck & Co., Inc., Kenilworth, New Jersey, USA.
V212 Protocol 001 Trial Group and V212 Protocol 011 Trial Group
Merck & Co., Inc., Rahway, NJ, USA (United States) · USHematology Oncology Consultants · USInfectious Disease Research Institute · USStanford University · USUniversity of California, Los Angeles · USUniversity of Chicago · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn phase 3 trials, inactivated varicella zoster virus (VZV) vaccine (ZV

methodsPatients were randomized to ZV

resultsEstimated geometric mean fold rise ratios (ZV

conclusionsZV CLINICAL

trial registrationNCT01229267, NCT01254630.

Indexed as

cell-mediated immunityhumoral immunityimmunocompromised adultsimmunogenicityinactivated zoster vaccine

Identifiers

PMID32665955
PMCPMC7336559
OpenAlexW3033566150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.